Imricor Medical Systems (ASX:IMR) Up 1.43% — MRI-Guided Heart Treatment Gaining Attention

Sonal Goyal

04 September 2026 05:33 PM AEST

Imricor Medical Systems (ASX:IMR) Up 1.43% — MRI-Guided Heart Treatment Gaining Attention

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

• Imricor Medical Systems gained 1.43% to $1.948 on 4 September 2026

• Company continues development of MRI-compatible cardiac ablation technology

• Advantage-MR EP system and related products remain the core commercial focus

• Disclosures cover European and US market progress alongside cash and regulatory updates

Imricor Medical Systems Inc (ASX:IMR) edged higher by 1.43% to $1.948 on 4 September 2026. The US-headquartered, ASX-listed medical device company is pioneering MRI-guided cardiac ablation procedures, a technology that has the potential to transform how arrhythmia treatments are performed by enabling real-time visualisation during the procedure.

About the Company

Imricor Medical Systems is a medical device company developing the world's first MRI-compatible cardiac ablation system. Its Advantage-MR EP system allows electrophysiology (heart ablation) procedures to be performed inside an MRI scanner, providing real-time, high-resolution soft tissue imaging that is not available with conventional X-ray guided systems. Imricor has received CE Mark approval in Europe and is pursuing regulatory clearance in the United States. The company is listed on the ASX and has its primary operations in Burnsville, Minnesota.

Key Developments

Imricor Medical Systems continues development and commercialisation of its MRI-compatible cardiac-ablation technology. The company's latest disclosures cover clinical and commercial activities surrounding the Advantage-MR EP system and related products. Its reporting also provides information on cash resources, operating expenditure, regulatory activities and progress across European and United States markets.

Key Catalysts to Watch

• US FDA regulatory clearance for the Advantage-MR EP system

• Expansion of European commercial sites and procedure volumes

• Clinical publications supporting MRI-guided ablation safety and efficacy

• Partnership or distribution agreements in key geographic markets

Risks

• US regulatory clearance remains pending, limiting the addressable market

• Capital requirements for clinical development and commercialisation

• Adoption risk in cardiac electrophysiology given existing X-ray workflow entrenchment

• Small commercial footprint and early-stage Revenue generation

Conclusion

Imricor Medical Systems represents one of the most genuinely differentiated medical device plays on the ASX. MRI-guided cardiac ablation is a compelling clinical concept, and the company's progress in Europe provides proof of concept for the technology. The 1.43% gain on 4 September reflects steady investor interest. US regulatory approval is the transformational catalyst that investors are waiting for. Until then, this remains a high-risk, high-reward opportunity for investors with a long time horizon.

FAQs

Q:Why did Imricor Medical Systems rise on 4 September 2026?

A:IMR gained 1.43% to $1.948, likely reflecting continued positive sentiment toward its MRI cardiac ablation technology and European commercial progress.

Q:What is the Advantage-MR EP system?

A:The Advantage-MR EP system is Imricor's MRI-compatible cardiac ablation platform that allows heart ablation procedures to be performed inside an MRI scanner, providing real-time soft tissue imaging.

Q:Does Imricor have US approval?

A:Imricor has CE Mark approval in Europe but is still pursuing US FDA regulatory clearance, which would be a major commercial milestone.

Q:Where is Imricor based?

A:Imricor Medical Systems is headquartered in Burnsville, Minnesota, USA. It is listed on the ASX despite being a US-based company.

Q:What are the risks for Imricor investors?

A:Key risks include pending US FDA clearance, high capital requirements, slow adoption in a traditionally X-ray-based clinical specialty, and early-stage revenue.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.